5% Therapeutic use of imiquimod cream

Junghee Yoon, Jae Eun Choi, Hyo Hyun Ahn, Young Chul Kye, Soo-Hong Seo

Research output: Contribution to journalReview article

Abstract

Background: Imiquimod is an immune response modifier that shows antiproliferative and antiviral characteristics through synthesis of multiple cytokines. Although it was originally approved by the Food and Drug Administration for the treatment of anogenital warts, it has also been successfully used to treat various skin conditions. Objective: The aim of this study was to evaluate the current usage of 5% imiquimod cream for the treatment of various skin conditions in dermatologie clinics. Methods: We reviewed the records of 270 patients with various skin conditions who were treated with 5% imiquimod cream. Data was collected through medical records, clinical photographs, and biopsy specimens. Results: Besides anogenital warts, 5% imiquimod cream has been prescribed in more than 20 skin conditions. The most common skin disease was verruca vulgaris. Others, in order of prevalence, were molluscum contagiosum, actinic keratosis, condyloma accuminatum, and verruca plana. Among the 270 patients who were treated with 5% imiquimod cream, more than two-thirds showed clinical response, but only 26 patients (9.7%) achieved clinical complete remission with median clearing time of 7.3 weeks. While applying 5% imiquimod cream, 82 patients (30.4%) experienced local side effects that were generally mild and generally well-tolerated. The most common side effect was erythema and the others, in order of prevalence, were oozing, itching sensation, burning sensation, scabbing, erosion and pain. No systemic side effects were found. Conclusion: Although 5% imiquimod cream is licensed in Korea only for treatment of adult anogenital warts, other skin diseases such as verruca vulgaris are more commonly the treatment target in dermatologie clinics. As the reported therapeutic effects are various, more clinical studies are required to assess the safety and efficacy of imiquimod for the treatment of various skin conditions.

Original languageEnglish
Pages (from-to)993-1001
Number of pages9
JournalKorean Journal of Dermatology
Volume49
Issue number11
Publication statusPublished - 2011 Nov 1

Fingerprint

imiquimod
Therapeutic Uses
Warts
Skin
Skin Diseases
Molluscum Contagiosum
Actinic Keratosis
Temazepam
United States Food and Drug Administration
Therapeutics
Erythema
Pruritus
Korea
Medical Records
Antiviral Agents

Keywords

  • Clinical use
  • Imiquimod
  • Skin disease

ASJC Scopus subject areas

  • Dermatology

Cite this

5% Therapeutic use of imiquimod cream. / Yoon, Junghee; Choi, Jae Eun; Ahn, Hyo Hyun; Kye, Young Chul; Seo, Soo-Hong.

In: Korean Journal of Dermatology, Vol. 49, No. 11, 01.11.2011, p. 993-1001.

Research output: Contribution to journalReview article

Yoon, Junghee ; Choi, Jae Eun ; Ahn, Hyo Hyun ; Kye, Young Chul ; Seo, Soo-Hong. / 5% Therapeutic use of imiquimod cream. In: Korean Journal of Dermatology. 2011 ; Vol. 49, No. 11. pp. 993-1001.
@article{1567065ef09c4f87a716dca64b6612e1,
title = "5{\%} Therapeutic use of imiquimod cream",
abstract = "Background: Imiquimod is an immune response modifier that shows antiproliferative and antiviral characteristics through synthesis of multiple cytokines. Although it was originally approved by the Food and Drug Administration for the treatment of anogenital warts, it has also been successfully used to treat various skin conditions. Objective: The aim of this study was to evaluate the current usage of 5{\%} imiquimod cream for the treatment of various skin conditions in dermatologie clinics. Methods: We reviewed the records of 270 patients with various skin conditions who were treated with 5{\%} imiquimod cream. Data was collected through medical records, clinical photographs, and biopsy specimens. Results: Besides anogenital warts, 5{\%} imiquimod cream has been prescribed in more than 20 skin conditions. The most common skin disease was verruca vulgaris. Others, in order of prevalence, were molluscum contagiosum, actinic keratosis, condyloma accuminatum, and verruca plana. Among the 270 patients who were treated with 5{\%} imiquimod cream, more than two-thirds showed clinical response, but only 26 patients (9.7{\%}) achieved clinical complete remission with median clearing time of 7.3 weeks. While applying 5{\%} imiquimod cream, 82 patients (30.4{\%}) experienced local side effects that were generally mild and generally well-tolerated. The most common side effect was erythema and the others, in order of prevalence, were oozing, itching sensation, burning sensation, scabbing, erosion and pain. No systemic side effects were found. Conclusion: Although 5{\%} imiquimod cream is licensed in Korea only for treatment of adult anogenital warts, other skin diseases such as verruca vulgaris are more commonly the treatment target in dermatologie clinics. As the reported therapeutic effects are various, more clinical studies are required to assess the safety and efficacy of imiquimod for the treatment of various skin conditions.",
keywords = "Clinical use, Imiquimod, Skin disease",
author = "Junghee Yoon and Choi, {Jae Eun} and Ahn, {Hyo Hyun} and Kye, {Young Chul} and Soo-Hong Seo",
year = "2011",
month = "11",
day = "1",
language = "English",
volume = "49",
pages = "993--1001",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "11",

}

TY - JOUR

T1 - 5% Therapeutic use of imiquimod cream

AU - Yoon, Junghee

AU - Choi, Jae Eun

AU - Ahn, Hyo Hyun

AU - Kye, Young Chul

AU - Seo, Soo-Hong

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background: Imiquimod is an immune response modifier that shows antiproliferative and antiviral characteristics through synthesis of multiple cytokines. Although it was originally approved by the Food and Drug Administration for the treatment of anogenital warts, it has also been successfully used to treat various skin conditions. Objective: The aim of this study was to evaluate the current usage of 5% imiquimod cream for the treatment of various skin conditions in dermatologie clinics. Methods: We reviewed the records of 270 patients with various skin conditions who were treated with 5% imiquimod cream. Data was collected through medical records, clinical photographs, and biopsy specimens. Results: Besides anogenital warts, 5% imiquimod cream has been prescribed in more than 20 skin conditions. The most common skin disease was verruca vulgaris. Others, in order of prevalence, were molluscum contagiosum, actinic keratosis, condyloma accuminatum, and verruca plana. Among the 270 patients who were treated with 5% imiquimod cream, more than two-thirds showed clinical response, but only 26 patients (9.7%) achieved clinical complete remission with median clearing time of 7.3 weeks. While applying 5% imiquimod cream, 82 patients (30.4%) experienced local side effects that were generally mild and generally well-tolerated. The most common side effect was erythema and the others, in order of prevalence, were oozing, itching sensation, burning sensation, scabbing, erosion and pain. No systemic side effects were found. Conclusion: Although 5% imiquimod cream is licensed in Korea only for treatment of adult anogenital warts, other skin diseases such as verruca vulgaris are more commonly the treatment target in dermatologie clinics. As the reported therapeutic effects are various, more clinical studies are required to assess the safety and efficacy of imiquimod for the treatment of various skin conditions.

AB - Background: Imiquimod is an immune response modifier that shows antiproliferative and antiviral characteristics through synthesis of multiple cytokines. Although it was originally approved by the Food and Drug Administration for the treatment of anogenital warts, it has also been successfully used to treat various skin conditions. Objective: The aim of this study was to evaluate the current usage of 5% imiquimod cream for the treatment of various skin conditions in dermatologie clinics. Methods: We reviewed the records of 270 patients with various skin conditions who were treated with 5% imiquimod cream. Data was collected through medical records, clinical photographs, and biopsy specimens. Results: Besides anogenital warts, 5% imiquimod cream has been prescribed in more than 20 skin conditions. The most common skin disease was verruca vulgaris. Others, in order of prevalence, were molluscum contagiosum, actinic keratosis, condyloma accuminatum, and verruca plana. Among the 270 patients who were treated with 5% imiquimod cream, more than two-thirds showed clinical response, but only 26 patients (9.7%) achieved clinical complete remission with median clearing time of 7.3 weeks. While applying 5% imiquimod cream, 82 patients (30.4%) experienced local side effects that were generally mild and generally well-tolerated. The most common side effect was erythema and the others, in order of prevalence, were oozing, itching sensation, burning sensation, scabbing, erosion and pain. No systemic side effects were found. Conclusion: Although 5% imiquimod cream is licensed in Korea only for treatment of adult anogenital warts, other skin diseases such as verruca vulgaris are more commonly the treatment target in dermatologie clinics. As the reported therapeutic effects are various, more clinical studies are required to assess the safety and efficacy of imiquimod for the treatment of various skin conditions.

KW - Clinical use

KW - Imiquimod

KW - Skin disease

UR - http://www.scopus.com/inward/record.url?scp=84555191826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555191826&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84555191826

VL - 49

SP - 993

EP - 1001

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 11

ER -